Viking Therapeutics: 38.5% Acquisition Odds by 2027 on Polymarket
Polymarket data shows a 38.5% implied probability that Viking Therapeutics will be acquired before 2027, with record volume on the contract. The company's obesity drug VK2735, a dual GLP-1/GIP agonist, is a key attraction for pharma giants like Eli Lilly and Pfizer.
Key Numbers
Polymarket, the decentralized prediction platform, is tracking Viking Therapeutics (NASDAQ: VKTX) as the biotech most likely to be acquired. According to the platform, the implied probability of an acquisition before 2027 stands at 38.5%, with all-time trading volume exceeding $1.68 million on that single contract.
Why Viking Therapeutics?
The primary driver is the booming obesity treatment market. Viking's VK2735, a dual GLP-1/GIP agonist, is arguably the most advanced obesity asset not owned by a major pharmaceutical company. This makes it an attractive acquisition target for giants like Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE), both seeking to expand their obesity portfolios.
Context
The obesity drug market is estimated to be worth tens of billions of dollars. Eli Lilly already markets Mounjaro (tirzepatide), while Pfizer is developing its own candidates. Acquiring Viking could give the buyer a significant competitive edge.
What This Means for Investors
For Viking shareholders, a potential acquisition could yield substantial returns, especially if the buyout price exceeds current valuations. However, the probability remains below 50%, meaning no acquisition is also possible. Any negative regulatory or clinical developments could derail the deal.
Frequently Asked Questions
Found this useful? Share it